RamaswamyGovindanMD

Oncology • Saint Louis, MO

Professor, Internal Medicine, Washington University School of Medicine

Join to view full profile

Dr. Govindan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Govindan's full profile

Already have an account?

Office
4921 Parkview Pl
# Dv
Saint Louis, MO 63110
Phone+1 800-647-2098

Fax+1 314-362-3192

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 1993 - 1996
University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 1991 - 1993
Stanley Medical College SMCClass of 1987

Certifications & Licensure

MO State Medical License 1995 - 2025
IL State Medical License 1996 - 1999

Awards, Honors, & Recognition

Alton Ochsner Award Related Smoking and Disease Alton Ochsner, 2016
Endowed Chair in Medical Oncology Anheuser Busch, 2016
CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

Gefitinib in Treating Patients With Malignant Mesothelioma Start of enrollment: 2001 Sep 01
Completed
Phase 2
Combination Chemotherapy and Exisulind in Treating Patients With Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2002 Jun 01
Completed
Phase 2
Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer Start of enrollment: 2005 Sep 01
Completed
Phase 2
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
Active, not recruiting
Phase 3
A Phase II Study of Radiation Therapy, Paclitaxel Poliglumex, and Carboplatin in Stage III Non-Small Cell Lung Cancer Start of enrollment: 2006 Apr 01
Terminated
Phase 2
FDG-PET/CT Scans in Patients With Stage IIIB or Stage IV NSCLC Undergoing Chemotherapy Start of enrollment: 2007 Mar 30
Terminated
Not Applicable
Differences in the Presentation Outcome and Response to Treatment Between Never- Smokers and Smokers With NSCLC Start of enrollment: 2006 Mar 01
Completed
Drug Delivery and Toxicities of Adjuvant Chemotherapy in Resected NCSLC Start of enrollment: 2006 Feb 01
Completed
A Phase I Study of SUNITINIB and Rapamycin in Advanced Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2007 Nov 01
Completed
Phase 1
Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide Start of enrollment: 2008 Mar 01
Active, not recruiting
Phase 3
Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer Start of enrollment: 2011 Jan 11
Terminated
Phase 3
Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer Start of enrollment: 2012 Mar 01
Completed
Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies Start of enrollment: 2013 May 07
Completed
Phase 1
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer Start of enrollment: 2013 Feb 01
Terminated
Phase 2, Phase 3
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors Start of enrollment: 2013 May 03
Terminated
Phase 1, Phase 2
Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib Start of enrollment: 2014 Jun 01
Withdrawn
Phase 2
Hypofractionated Proton Beam Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Stage II-III Non-Small Cell Lung Cancer Start of enrollment: 2014 May 22
Completed
Phase 1
Pazopanib in Molecularly Selected Patients With Advanced NSCLC Start of enrollment: 2015 Apr 27
Terminated
Phase 2
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) Start of enrollment: 2015 Feb 11
Active, not recruiting
Phase 3
A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer Start of enrollment: 2015 Aug 06
Completed
Phase 2
Afatinib Genomic Landscape Start of enrollment: 2015 Jun 11
Terminated
Genomic Landscape of Ceritinib Start of enrollment: 2015 Sep 16
Terminated
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors Start of enrollment: 2016 Sep 12
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

1594 citations
Pan-cancer analysis of whole genomes
Peter J. Campbell, Gad Getz, Jan O. Korbel, Joshua M. Stuart, Jennifer L. Jennings
Nature. 2020-02-06
3881 citations
Comprehensive molecular profiling of lung adenocarcinoma: The cancer genome atlas research network
Eric A. Collisson, Joshua D. Campbell, Angela N. Brooks, Alice H. Berger, William Lee
Nature. 2014-01-01
685 citations
Sotorasib for Lung Cancers with KRAS p.G12C Mutation.
Ferdinandos Skoulidis, Bob T. Li, Grace K. Dy, Timothy J. Price, Gerald Steven Falchook
The New England Journal of Medicine. 2021-06-04

Journal Articles

A Deep Learning Approach to Automate Refinement of Somatic Variant Calling from Cancer Sequencing Data
Ravindra Uppaluri, Gavin P Dunn, Ramaswamy Govindan, S Joshua Swamidass, Todd A Fehniger, Nature
Targeting Resistance to Targeted Therapies: Combating a Resilient Foe
Siddhartha Devarakonda, Ramaswamy Govindan, Clinical Cancer Research
Recurrent WNT Pathway Alterations Are Frequent in Relapsed Small Cell Lung Cancer
Saiama N. Waqar, Daniel Morgensztern, Robert S. Fulton, Ramaswamy Govindan, Nature

Lectures

An open-label, phase 1b study of NEO-PV-01 with pembrolizumab plus chemotherapy in patients with advanced or metastatic nonsquamous non-small cell lung cancer.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Great Debates and Updates In Thoracic Malignancies
Imedex, San Francisco, California - 5/5/2012

Press Mentions

Washington University School of Medicine Investigators Probe Gene & Protein-Level Patterns Behind Lung Cancer RecurrenceJune 30th, 2022
$5.3M Grant Funds Washington University School of Medicine Lung Cancer Recurrence ResearchJune 29th, 2022
$5.3 Million Grant Supports Research into Lung Cancer RecurrenceJune 28th, 2022
Join now to see all

Committees

Member, International Association for the Study of Lung Cancer Core Program 2014 - Present
Member, ALCHEMIST Champions Team 2014 - Present
Member, SITC/Medscape CME Project Steering Committee 2014 - Present
Member, National Comprehensive Cancer Network (NCCN) National Cancer Institute (NCI) Non-Small Cell Lung Cancer Panel 2013 - Present
Chair, IASLC Pathology Committee 2012 - Present